Q4 2018 EPS Estimates for Amgen, Inc. Boosted by Analyst (NASDAQ:AMGN)

Amgen, Inc. (NASDAQ:AMGN) – Stock analysts at Leerink Swann boosted their Q4 2018 earnings per share estimates for Amgen in a note issued to investors on Friday, according to Zacks Investment Research. Leerink Swann analyst G. Porges now expects that the medical research company will earn $3.34 per share for the quarter, up from their previous estimate of $3.03. Leerink Swann has a “Market Perform” rating on the stock.

AMGN has been the topic of several other research reports. Mizuho reissued a “buy” rating and issued a $200.00 price target (up previously from $192.00) on shares of Amgen in a research note on Monday. Morgan Stanley decreased their price objective on Amgen from $204.00 to $196.00 and set an “overweight” rating for the company in a report on Friday, February 2nd. Zacks Investment Research cut Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Royal Bank of Canada reduced their price target on Amgen from $192.00 to $188.00 and set a “sector perform” rating for the company in a report on Thursday, October 26th. Finally, BMO Capital Markets raised their price objective on shares of Amgen from $192.00 to $202.00 and gave the stock a “market perform” rating in a research report on Friday, February 2nd. Sixteen investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $191.84.

Amgen (NASDAQ:AMGN) traded up $1.72 on Monday, hitting $175.18. The company’s stock had a trading volume of 1,562,396 shares, compared to its average volume of 3,780,000. Amgen has a 1 year low of $152.16 and a 1 year high of $201.23. The firm has a market cap of $127,220.00, a P/E ratio of 67.90, a price-to-earnings-growth ratio of 2.13 and a beta of 1.42. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. During the same period in the prior year, the business earned $2.89 EPS. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year.

A number of hedge funds have recently modified their holdings of AMGN. Baker Ellis Asset Management LLC bought a new position in shares of Amgen during the 3rd quarter valued at approximately $108,000. Jackson Grant Investment Advisers Inc. grew its position in shares of Amgen by 0.8% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after acquiring an additional 5 shares during the period. Phocas Financial Corp. bought a new position in shares of Amgen during the 2nd quarter valued at approximately $110,000. Barrow Hanley Mewhinney & Strauss LLC grew its position in shares of Amgen by 110.7% during the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 647 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 340 shares during the period. Finally, Omnia Family Wealth LLC grew its position in shares of Amgen by 25.3% during the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock valued at $125,000 after acquiring an additional 147 shares during the period. 78.95% of the stock is owned by institutional investors and hedge funds.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $185.62, for a total value of $283,070.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.19% of the company’s stock.

Amgen declared that its board has authorized a share buyback plan on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be given a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a yield of 3.01%. This is an increase from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date of this dividend is Wednesday, February 14th. Amgen’s dividend payout ratio is presently 178.29%.

TRADEMARK VIOLATION WARNING: “Q4 2018 EPS Estimates for Amgen, Inc. Boosted by Analyst (NASDAQ:AMGN)” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/02/12/amgen-inc-amgn-to-post-q4-2018-earnings-of-3-34-per-share-leerink-swann-forecasts-updated.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Get a free copy of the Zacks research report on Amgen (AMGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply